Related by context. All words. (Click for frequent words.) 80 5 FU leucovorin 79 systemic anaplastic large 79 TO AVOID PREGNANCY WHILE 79 PNP inhibitor 79 dasatinib Sprycel ® 78 R sorafenib tablets 78 FOLFOX6 chemotherapy regimen 78 sorafenib tablets 78 refractory cutaneous T 78 Peginterferon alfa 2b 78 generation purine nucleoside 77 SPRYCEL ® 77 AVASTIN 77 Ph + acute lymphoblastic 77 FOLOTYN ® 77 TRIOLEX HE# APOPTONE HE# 77 erlotinib Tarceva ® 77 R lenalidomide 77 LymphoStat B belimumab 77 FEMALES SHOULD BE ADVISED 77 CYT# potent vascular disrupting 77 Vidaza ® 77 alfa 2a 77 refractory acute myeloid 76 irinotecan doxorubicin oxaliplatin paclitaxel 76 ® lenalidomide 76 MAGE A3 ASCI 76 novel VDA molecule 76 PEGylated anti 76 bevacizumab Avastin R 76 non nucleoside inhibitor 76 interferon gamma 1b 76 lintuzumab SGN 76 myelodysplastic myeloproliferative diseases 76 relapsed refractory multiple myeloma 76 chemosensitizer 76 Kit CD# positive 76 metastatic malignant 76 novel emulsion formulation 76 substantially excreted 76 aplastic anemia AA 76 hypereosinophilic syndrome 75 virus HCV protease inhibitor 75 leukemia CLL 75 R Saizen R 75 cisplatin gemcitabine 75 Annamycin 75 refractory acute promyelocytic 75 XL# anticancer compounds 75 cetuximab Erbitux R 75 leukemia AML 75 interferon beta 1a infertility 75 Evoltra ® 75 evaluating satraplatin 75 Relapsed Refractory 75 candidates Azedra TM 75 irinotecan containing 75 plus dacarbazine 75 vapreotide acetate 75 dasatinib Sprycel 75 Cutaneous T 75 5 fluorouracil leucovorin 75 alvespimycin 75 orally administered inhibitor 75 Copegus ® 75 Panzem R 75 CDK cyclin dependent 75 tumors GIST 75 Vidaza R 75 chronic eosinophilic leukemia 75 induced macular edema 75 Personalized Immunotherapy 75 Completes Patient Enrollment 75 Hsp# Inhibitor 75 Cloretazine 75 Phase #b/#a clinical 75 Fludara ® 75 cell lymphoma CTCL 74 PDX pralatrexate 74 evaluating tivozanib 74 cetuximab Erbitux ® 74 Crofelemer budesonide foam 74 LymphoStat B TM 74 Initiate Clinical Trial 74 Omacetaxine 74 pan histone deacetylase 74 pralatrexate injection folate analogue 74 Cloretazine ® 74 Zorbtive TM 74 developing Bicifadine serotonin 74 refractory indolent non 74 refractory Hodgkin lymphoma 74 oral ridaforolimus 74 evaluating picoplatin 74 IMPDH inhibitor 74 Hormone Refractory Prostate Cancer 74 cutaneous T 74 Xeloda ® 74 oral prodrug 74 thalidomide Thalomid 74 carcinoma mCRC 74 pediatric acute lymphoblastic 74 trastuzumab Herceptin R 74 Dementia Related Psychosis 74 cell carcinoma RCC 74 essential thrombocythemia ET 74 lenalidomide Revlimid R 74 previously untreated follicular 74 oropharyngeal candidiasis OPC 74 sarcoma melanoma 74 MyVax R 74 targeted radiotherapeutic 74 Clolar ® 74 personalized cellular immunotherapy 74 galiximab 74 bortezomib Velcade R 74 ara C 74 Panzem R NCD 74 forodesine 74 VEGFR2 inhibitor 74 2 methoxyestradiol 74 methylnaltrexone bromide 74 Meets Primary Endpoint 74 Azacitidine 74 advanced metastatic renal 73 Pegasys ® 73 Serostim ® 73 GVAX ® 73 recurrent metastatic ovarian cancer 73 Tarceva TM 73 PRN FDA Approves 73 IMiDs ® compound 73 antibody MAb 73 Telik logo TELINTRA 73 TNF Tumor Necrosis Factor 73 plus prednisone prednisolone 73 COPEGUS R 73 AAG geldanamycin analog 73 capecitabine Xeloda 73 dependent kinase inhibitor 73 refractory multiple myeloma 73 Combination REOLYSIN R 73 Luveris R Ovidrel R 73 INSPIRE Trial Phase III 73 Albuferon TM 73 hyperphenylalaninemia HPA due 73 Panzem NCD 73 Ovitrelle R Serostim 73 ALN HPN 73 cyclophosphamide doxorubicin vincristine 73 metastatic pancreatic 73 investigational oral hepatitis C 73 docetaxel Taxotere ® 73 dextromethorphan quinidine 73 ® bortezomib 73 HGS ETR2 73 sapropterin dihydrochloride 73 Complicated Skin 73 Amigal TM 73 paclitaxel Taxol ® 73 Campath alemtuzumab 73 stage IIIb IV 73 relapsed MM 73 Lenalidomide 73 MEK Inhibitor 73 metastatic colorectal carcinoma 73 CYP#A# CYP#D# 73 bevacizumab Avastin ® 73 Initiates Enrollment 73 Receives Orphan Drug Designation 73 relapsed acute myelogenous 73 IgG1 monoclonal antibody 73 Folfox 73 PI3K/Akt pathway inhibitor 73 resistant hormone refractory 73 anthracycline taxane 73 oral picoplatin 73 acetonide FA 73 Copegus R 73 EGFR expressing mCRC 73 BCG refractory carcinoma 73 indolent follicular non 73 Ribavirin causes 73 IMiDs ® 73 sunitinib Sutent ® 73 docetaxel Taxotere R 73 TELINTRA R 73 metastatic hormone refractory 73 Zenvia ™ 73 Granted Orphan Drug 73 vinca alkaloid 73 gemcitabine cisplatin 73 corticotropin injection 73 histone deacetylase HDAC inhibitor 72 kidney urologic 72 FUSILEV enhances 72 K ras mutations 72 Patients Treated With 72 lymphoid malignancies 72 metastatic castration resistant 72 acyclovir Lauriad R 72 Romidepsin 72 Pegloticase 72 Vitrasert R 72 relapsed multiple myeloma 72 PEGylated Fab fragment 72 Aflibercept 72 metastatic castrate resistant 72 sunitinib Sutent 72 Wafer polifeprosan 72 imatinib Gleevec ® 72 gemcitabine Gemzar ® 72 EGFr expressing metastatic colorectal 72 novel synthetic PEGylated 72 receptor tyrosine kinase inhibitor 72 HGS ETR1 mapatumumab 72 Gemzar ® 72 Mg Usa 72 Amgen Neulasta R 72 plus fludarabine 72 bladder ovarian 72 brand ciclesonide HFA 72 CIMZIA TM certolizumab pegol 72 Kuvan R 72 Vidaza azacitidine 72 infliximab monotherapy 72 Quinamed 72 R roscovitine CDK cyclin 72 YONDELIS 72 arsenic trioxide injection 72 accumulate preferentially 72 tumor activated prodrug 72 oncolytic virus therapies 72 radiation sensitizer 72 Tezampanel 72 Initiates Phase II 72 intravesical infusion therapy 72 LHRH receptor positive 72 systemic juvenile idiopathic 72 mitoxantrone plus 72 Nexavar ® 72 damage cirrhosis liver 72 CTAP# Capsules 72 peptidic compound 72 novel histone deacetylase 72 FOLFOX6 72 DIFICID ™ 72 By JENNIFER LEARN 72 recurrent NSCLC 72 modified glutathione analog 72 thetreatment 72 recurrent glioblastoma multiforme 72 CD# CEA 72 Refractory Hodgkin Lymphoma 72 Investigational Treatment 72 Amgen Neulasta ® 72 Tiuxetan 72 progressive metastatic prostate 72 Brentuximab Vedotin SGN 72 Antitumor Activity 72 formerly LymphoStat B 72 Adjuvant Treatment 72 RANK Ligand inhibitor 72 dihydrochloride Tablets 72 liposomal formulation 72 humanized therapeutic 72 gastrointestinal stromal 72 Pemetrexed 72 IMiDs R 72 IL# PE#QQR 72 GTC recombinant human 72 refractory peripheral T 72 PEGINTRON TM 72 unresectable recurrent 72 ATRA IV 72 Mg Uk 72 Epothilone D 72 Phase 2b Clinical Trial 72 TELINTRA 72 evaluating Xcytrin 72 hormone refractory metastatic prostate 72 oral nucleoside analogue 71 individualized cellular immunotherapy 71 NS5B polymerase 71 Begins Dosing 71 Epratuzumab 71 FDA APPROVES 71 hematological cancers notably 71 Letairis ambrisentan 71 Bayer HealthCare Onyx Pharmaceuticals 71 panitumumab Vectibix R 71 JAK2 Inhibitor 71 Pharmacokinetics PK 71 demonstrated antitumor activity 71 Xelox 71 metastatic GIST 71 severe hypercholesterolemia 71 Navelbine ® 71 non metastatic resectable 71 MGd 71 Xcytrin R 71 ZOLINZA 71 subependymal giant cell 71 non porcine pancreatic 71 evaluating Actimmune 71 potentially hepatotoxic 71 sargramostim 71 investigational oral inhibitor 71 Philadelphia Chromosome Positive 71 primary hypercholesterolemia 71 pentadentate logo R 71 monoclonal antibody IgG1 Mab 71 depressive episodes associated 71 investigational monoclonal antibody 71 Gel repository corticotropin injection 71 IAP inhibitor 71 Irinotecan 71 Naive Patients 71 delivers fluocinolone acetonide FA 71 leukemia APL 71 Ixempra 71 DNA methyltransferase inhibitors 71 Pivotal Phase III 71 relapsed leukemia 71 Elagolix 71 gemcitabine chemotherapy 71 Severe Sepsis 71 temsirolimus Torisel ® 71 unresectable locally advanced 71 Onrigin 71 Voreloxin 71 carcinoma HCC 71 induced mucositis 71 Interferon beta 1a 71 FUSILEV ® 71 plus DOXIL 71 arthritis PsA 71 VELCADE melphalan 71 prokinetic agent 71 sorafenib Nexavar 71 Neulasta R 71 hyaluronidase enzyme 71 humanized interleukin 6 71 evaluating T DM1 71 nilotinib Tasigna ® 71 Glufosfamide 71 elderly myelodysplastic syndromes 71 PrevOnco ™ 71 commercialize deforolimus 71 Submits NDA 71 Atripla combines 71 Thiarabine 71 phase IIb clinical 71 Leukine ® 71 PrevOnco 71 ALN PCS 71 BENLYSTA ® 71 TRANSDUR ™ 71 Acute Myeloid Leukemia AML 71 ® decitabine 71 Amrubicin 71 Initiates Clinical Trial 71 topically applied SEPA 71 Cimzia TM 71 ELACYT 71 histone deacetylase inhibitor 71 sunitinib malate 71 IN PATIENTS WITH 71 transthyretin mediated amyloidosis ATTR 71 Vascular Disrupting Agent 71 Solazed TM 71 ribavirin RBV 71 Cimzia ® certolizumab pegol 71 receiving INTRON 71 ongoing Phase 1b 71 Initiate Phase 71 DOXIL 71 fluoropyrimidine 71 chronic myeloid 71 TRANSDUR ® 71 IMiDs 71 doxorubicin HCl liposome injection 71 sorafenib Nexavar ® 71 HuMax 71 CIMZIA r certolizumab pegol 71 investigational immunotherapy 71 weekly subcutaneous injections 71 Initiates Phase III 71 biologic DMARD 71 Soft Tissue Sarcoma 71 oral proteasome inhibitor 71 vinorelbine tartrate 71 Ceflatonin 71 alpha folate receptor 71 antiangiogenesis therapies 71 Exelixis compounds 71 remission induction 70 MKC# MT 70 Advanced Renal Cell 70 refractory AML 70 following fluoropyrimidine oxaliplatin 70 ThermoDox ® clinical 70 plus prednisone 70 PROCTOCORT ® Suppository Hydrocortisone 70 Achieves Primary Endpoint 70 OMNARIS HFA 70 triggers apoptosis programmed 70 lumiliximab 70 octreotide implant 70 Chronic lymphocytic leukemia CLL 70 gefitinib Iressa 70 Oral Fingolimod 70 Prednisone Against Refractory 70 Phase IIb Trial 70 Myelodysplastic Syndrome MDS 70 VIVITROL ® 70 dacarbazine DTIC 70 Campath ® 70 chemotherapy cisplatin 70 Frozen Shoulder syndrome Adhesive 70 Cardium Therapeutics TM 70 8mg/kg 70 infusional 5-FU/LV 70 DOXIL R 70 hoFH 70 Immunotherapeutic 70 PEGASYS ® 70 Atypical Hemolytic Uremic Syndrome 70 etanercept Enbrel 70 Chronic Lymphocytic Leukemia CLL 70 ThermoDox R 70 pan HDAC inhibitor 70 Metastatic Melanoma 70 Boxed Warnings 70 adalimumab Humira 70 multiple myeloma MM 70 miconazole Lauriad ® 70 inhalation powder 70 Gamunex C 70 melphalan prednisone 70 Presents Preclinical Data 70 octreotide acetate 70 Nexavar tablets 70 monoclonal antibody conjugated 70 treat chronic sinusitis 70 Veronate R 70 NASH Huntington 70 hormone LHRH antagonist 70 agonistic human 70 phase III isavuconazole 70 novel orally inhaled 70 mertansine 70 Elotuzumab 70 registrational Phase 70 lenalidomide Revlimid ® 70 oral chemotherapeutic agent 70 rheumatoid arthritis inflammatory bowel 70 AVONEX ® 70 esophageal candidiasis 70 ocular formulation 70 Peginterferon alfa 2a 70 advanced hepatocellular carcinoma 70 Inhalation Aerosol 70 cancer neuroendocrine tumor 70 cutaneous T cell 70 5q MDS 70 rALLy clinical trial 70 exocrine pancreatic insufficiency EPI 70 OMP #R# 70 Onyx Pharmaceuticals Announces 70 HCV RNA polymerase 70 complement inhibitor eculizumab 70 Romiplostim 70 including thyroiditis RA 70 FOLFOX chemotherapy 70 psoriasis rheumatoid arthritis 70 Altera Nebulizer System 70 trastuzumab DM1 T DM1 70 mapatumumab 70 pegylated interferon alfa 2a 70 systemic ALCL 70 non splenectomized 70 KNS # 70 adecatumumab MT# 70 investigational pharmacologically unique 70 beta 1a 70 Seliciclib CYC# 70 RhuDex TM 70 GW# [003] 70 acute myeloid 70 SinuNase TM 70 metaglidasen 70 sapropterin dihydrochloride Tablets 70 sapacitabine CYC# 70 Previously Treated 70 catheter occlusion 70 gastrointestinal stromal tumor GIST 70 ELADUR ™ 70 R metformin Concor 70 unique alkylating agent 70 Fludarabine 70 molecular imaging radiopharmaceutical 70 Septin9 biomarker 70 temsirolimus Torisel 70 2 inhibitor CYT# 70 non constipating irritable 70 RhuDex R 70 toenail onychomycosis 70 unresectable tumors 70 DEB# 70 Acetate Rectal Suppositories 70 lymphoma CTCL 70 Pruvel TM 70 Phase 2a Trial 70 5 lipoxygenase inhibitor 70 leukemia multiple myeloma 70 candesartan cilexetil 70 IMA# 70 Reports Preclinical Data 70 cell chronic lymphocytic 70 Generx TM 70 Bezielle 70 anthracycline containing 70 R MSCRAMM 70 Hodgkin lymphoma HL 70 Files IND 70 MCSP respectively 70 EGFr expressing mCRC 70 papillary renal cell carcinoma 70 Alfacell proprietary ribonuclease 70 Prolongs Survival 70 refractory gout 70 lexidronam injection 70 refractory acute lymphoblastic 70 Seliciclib 70 HGS ETR1 70 intranasal formulation 70 Daclizumab 70 Advanced Melanoma 70 whose tumors overexpress 70 HGS# 70 Platinol ® 70 EOquin TM 70 Syndrome LEMS 70 Refractory Peripheral T 70 Leukemias 70 Paraplatin ® 70 small lymphocytic lymphoma 70 Emtriva Viread 70 refractory NSCLC 70 Hedgehog Pathway Inhibitor 70 CYP#A# isoenzyme 70 cortisol synthesis 70 anti PlGF 70 Gonal f R follitropin 70 demethylating agent 70 Oral NKTR 70 Temsirolimus 70 Darinaparsin 70 Soliris TM eculizumab 70 relapsing remitting MS RRMS 70 TBC# 70 Zevalin R Ibritumomab 70 Fast Track Status 70 anthracyclines taxanes 70 R bendamustine hydrochloride 70 markets HP Acthar 69 CINQUIL 69 PF # [002] 69 Fludara 69 telaprevir dosed 69 Diffuse Large B 69 Bosutinib 69 Study Evaluating 69 cyclophosphamide methotrexate 69 smoldering multiple myeloma 69 Clofarabine 69 huN# DM1 69 ALN TTR 69 Peginterferon 69 radiation chemoradiation 69 Drug Candidate 69 Vitaxin 69 relapsed acute lymphoblastic 69 humanised monoclonal antibody 69 Nexavar prescribing 69 rheumatoid arthritis RA psoriatic 69 tyrosine kinase inhibitor TKI 69 Novel Oral 69 Triapine R 69 Nexavar sorafenib 69 ACTEMRA TM 69 multicenter Phase III 69 recurrent metastatic 69 TLK# 69 opioid induced constipation OIC 69 bone marrow reticulin deposition 69 ribavirin Copegus ® 69 Perifosine KRX 69 Archexin 69 OSI Tarceva 69 successfully commercialize Iluvien 69 haematologic 69 selective A2A adenosine receptor 69 hypertrichosis occurred 69 Vandetanib 69 ritonavir boosted 69 RhuDex ® 69 nilotinib Tasigna 69 oxaliplatin Eloxatin 69 Budesonide foam crofelemer 69 TRACON Pharmaceuticals 69 Xanafide 69 R bisoprolol Euthyrox 69 FDA Accepts 69 Receives Fast Track 69 e antigen HBeAg 69 paclitaxel poliglumex 69 Phase III Trial 69 J Antimicrob Chemother 69 omacetaxine mepesuccinate 69 non metastatic osteosarcoma 69 adenosine injection 69 Tipranavir 69 DAVANAT 69 5 FU capecitabine 69 Junovan TM 69 reduce serum phosphate 69 EGFR expressing metastatic colorectal 69 non peptidic protease 69 Clevudine 69 BiovaxID TM 69 vaginal candidiasis 69 Announces Tentative Approval 69 ONCASPAR 69 Tibotec Therapeutics division 69 small molecule Hedgehog 69 atypical Hemolytic Uremic Syndrome 69 refractory CLL 69 treats paroxysmal nocturnal 69 ® adefovir dipivoxil 69 PROVENGE ® 69 novel nucleoside analog 69 HER2 positive metastatic breast 69 XP# XP# 69 biliary tract cancer 69 Safinamide 69 combining voreloxin 69 Velcade bortezomib 69 refractory Ph + 69 Myelodysplastic Syndrome 69 class anticancer quinolone 69 Ozarelix 69 memantine HCl 69 Mylan Receives Approval 69 Presents Preclinical 69 novel tubulin binding 69 Zenvia TM 69 PANVAC VF 69 Camptosar ® 69 PEGylated interferon 69 abacavir lamivudine 69 tumor xenograft models 69 ISTODAX ® 69 gemcitabine carboplatin 69 deCODE ProstateCancer TM 69 Copegus ribavirin 69 interferon alfa 2b 69 denileukin diftitox 69 HP Acthar Gel repository 69 TTF Therapy 69 Factor Receptor 69 Peginterferon Alfa 2a 69 erlotinib Tarceva R 69 Vicinium TM 69 GAMMAGARD 69 NS5b 69 Lambert Eaton Myasthenic 69 alpha interferons 69 selective modulator 69 Phase 2b Trial 69 Adjunctive Therapy 69 XL# XL# XL# XL# 69 potent CYP#A# inhibitors 69 Temodar ® 69 SNT-MC#/idebenone 69 mGluR5 negative 69 Prodarsan R 69 pertuzumab 69 HBeAg negative 69 topical gel formulation 69 ceftazidime 69 Aeolus Pharmaceuticals Announces 69 sulfonylurea glimepiride 69 Solzira TM 69 Xcellerated T Cells 69 Lymphocytic 69 metastatic HER2 negative 69 relapsing multiple sclerosis 69 nephropathic cystinosis 69 Levoleucovorin 69 phenylketonuria PKU developed 69 Orally administered 69 Deforolimus 69 bendamustine ifosfamide 69 refractory Hodgkin 69 Investigational Oral 69 please visit http:/www.vandapharma.com 69 Ocrelizumab 69 MOVIPREP R 69 ovarian esophageal 69 interferon alpha IFN 69 orally inhaled migraine 69 mTOR mammalian target 69 Sapacitabine 69 familial amyloidotic polyneuropathy FAP 69 XL# XL# 69 diarrhea predominant irritable 69 ospemifene 69 R rilonacept Injection 69 oral beclomethasone dipropionate 69 pharmacogenomic translational research 69 severe hepatomegaly 69 Treatment Naïve 69 orally administered synthetic retinoid 69 PROCTOCORT R Suppository Hydrocortisone 69 TNF alpha selectively neutralizing 69 iobenguane 69 Intravenous CP 69 YOUR LOCAL ANIMAL SHELTER 69 approved incretin mimetic 69 Trastuzumab DM1 69 GTC recombinant form 69 Granulocyte Colony Stimulating Factor 69 CHEAP ONLINE PHARMACY LOW 69 Ceflatonin ® 69 vaccines oncolytic virus 69 systemic lupus erythematosus psoriasis 69 Presents Positive 69 human IgG1 monoclonal 69 sodium Injection 69 Pegylated interferon 69 q8h 69 TM pralatrexate injection 69 relapsed mantle 69 CIMZIA ™ 69 peginterferon alfa 2a Pegasys 69 antibody MT# 69 tenofovir emtricitabine 69 proprietary polysaccharide 69 THR beta agonist 69 LungAlert TM 69 Demonstrates Significant 69 tiuxetan 69 combines bupropion 69 CHOP cyclophosphamide doxorubicin vincristine 69 Protease Inhibitor 69 4mg/kg 69 plus COPEGUS 69 COLAZAL R 69 Oracea TM 69 VNP#M 69 refractory metastatic 69 low dose cytarabine 69 nephropathic cystinosis cystinosis 69 Decitabine 69 mTOR inhibitor 69 B CLL 69 Spiegelmer ® 69 alkylating agent 69 BYETTA ® 69 3 registrational trial 69 naïve HCV 69 Dacogen injection 69 BENLYSTA TM 69 allosteric modulator NAM 69 included exfoliative dermatitis 69 Navelbine R 69 Cloretazine R VNP#M 69 adriamycin 69 Receives Orphan Drug 69 PEG IFN 69 refractory colorectal cancer 69 Abiraterone acetate 69 myocardial infarction ventricular fibrillation 69 dimebon latrepirdine 69 standard chemotherapy regimen 69 Randomized Double blind 69 non squamous 69 reslizumab 69 Chronic lymphocytic leukemia 69 Iluvien ® 69 Demonstrates Positive 69 NDA Submission 69 Initiates Clinical 69 myelofibrosis polycythemia vera 69 HCV NS5B polymerase 69 HuMax EGFr 69 ODT metoclopramide HCl PEPCID 69 cyclophosphamide chemotherapy 69 Aplidin 69 volociximab 69 Pralatrexate 69 sorafenib Nexavar R 69 Liprotamase 69 non resectable metastatic 69 telomerase therapeutic 69 Gleevec resistant 69 Tasigna nilotinib 69 topoisomerase II inhibitor 69 CD4 monoclonal antibody 69 Phase 1b clinical trials 69 SUTENT ® 68 purpura ITP 68 Thalomid ® 68 oral rivaroxaban 68 THAT ARE DIFFICULT TO 68 REVLIMID lenalidomide 68 targeting CD# 68 cancer mCRC 68 ergot derivatives 68 gastrointestinal disorders ATI 68 cardiometabolic diseases Glucophage 68 candidate XP# 68 thymalfasin 68 atypical hemolytic uremic syndrome 68 ORENCIA ® 68 Entereg TM 68 Plicera 68 Trial Evaluating 68 ™ pralatrexate injection 68 seliciclib CYC# 68 mocetinostat MGCD# 68 R Bortezomib 68 highly purified pasteurized 68 Phase Ib clinical trials 68 systemic Phase 1b 68 forodesine purine nucleoside phosphorylase 68 inflammatory PDE 68 alefacept 68 pharmacologically active isomer 68 mg q#h 68 investigational antiplatelet agent 68 Heterozygous Familial Hypercholesterolemia 68 Canvaxin TM 68 develop HBV reactivation 68 ALTROPANE R 68 Nabi HB Intravenous 68 Phase Ib IIa 68 targeted antifolate 68 NeuroSTAT ® 68 pentostatin 68 Modrenal R 68 BARACLUDE R 68 omega interferon 68 Triapine 68 anti atherothrombotic 68 Silodosin 68 BRIM3 68 phenyl salicylate methylene blue 68 Familial Adenomatous Polyposis FAP 68 Orphan Drug status 68 NPC 1C 68 immunotherapeutic agent 68 HCl PEPCID ® famotidine 68 dirucotide MBP# 68 hepatitis C HCV 68 Azedra 68 BRIM2 68 Shows Promise Against 68 alpha1 antitrypsin deficiency 68 chemotherapy FOLFOX 68 Omnitarg 68 NU# direct 68 herpetic keratitis 68 Genotyping Test 68 Kuvan sapropterin dihydrochloride 68 Submits Biologics License Application 68 CG# oncolytic virus 68 Phase #/#a trial 68 markets COLAZAL 68 ENL recurrence 68 Metastatic Colorectal Cancer 68 proteasome inhibitor 68 TAXOTERE R 68 induce diuresis 68 metastatic ocular 68 Randomized Phase II 68 either acutely decompensated 68 Pertuzumab 68 small molecule thrombopoietin 68 INCB# [001] 68 Phase 2b Study 68 everolimus tablets 68 colesevelam HCl 68 Lenocta 68 polycythemia vera essential thrombocythemia 68 Recurrent Glioblastoma 68 Cleviprex TM clevidipine 68 plus Copegus 68 Arzerra ofatumumab 68 Therapeutic Competitors Companies 68 Adenoscan R 68 Pegylated Liposomal Doxorubicin 68 Aplidin R 68 gemtuzumab ozogamicin 68 erythematosus 68 elotuzumab 68 evaluating satraplatin plus 68 DNA demethylating agent 68 XYOTAX TM 68 docetaxel Injection Concentrate 68 Raptiva ® 68 cause cardiac channelopathies 68 Bayer Nexavar 68 peginterferon alpha 2a 68 Platinol ® cisplatin 68 By JAMAAL ABDUL 68 patients coinfected 68 cytarabine daunorubicin 68 Phase IIa Clinical Trial 68 metastatic gastric 68 Simulect 68 Genasense ® oblimersen 68 Multiple Myeloma MM 68 Nilotinib 68 JAK2 inhibitor 68 autologous cellular immunotherapy 68 myelodysplastic syndromes MDS 68 TELCYTA 68 Bendamustine 68 Initiates Phase 2b 68 ZACTIMA 68 histamine dihydrochloride 68 CIMZIA TM 68 carmustine 68 CYP#A# substrate 68 chronic idiopathic thrombocytopenic purpura 68 gemcitabine Gemzar 68 pegylated interferon peg IFN 68 undergoing hematopoietic stem 68 oral dual endothelin 68 VISICOL R 68 D aspartate NMDA receptor 68 antiangiogenic agent 68 trastuzumab Herceptin ® 68 phase IIb study 68 pseudobulbar affect PBA 68 AS# amonafide L malate 68 Humanized Anti 68 bortezomib Velcade 68 CHOP chemotherapy 68 Tanespimycin 68 ADP receptor antagonist 68 inflammatory autoimmune diseases 68 AEG# 68 pegylated interferons 68 liver resection surgeries 68 Oral Calcitonin 68 Marqibo TM 68 R bortezomib 68 estramustine 68 leukemia ALL 68 paclitaxel Taxol R 68 bucindolol hydrochloride 68 Xyfid TM 68 decompensated liver disease 68 TYGACIL 68 stage IIIB 68 Peg IFN 68 Alocrest 68 abatacept Orencia 68 INTEGRILIN ® 68 targets Galectin receptors 68 Suppository Hydrocortisone Acetate Rectal 68 FOLFIRI chemotherapy 68 R vitespen 68 FOLFIRI 68 Myelofibrosis 68 Retisert R 68 alpha 2b 68 GATTEX ™ 68 Onalta ™ 68 Trastuzumab Herceptin 68 influenza BCX# purine nucleoside 68 refractory chronic myeloid 68 Insegia 68 BARACLUDE ® 68 prednisone CHOP 68 follicular lymphoma FL 68 Solazed ™ 68 neratinib 68 metastatic androgen independent 68 Aviptadil 68 pegylated liposomal doxorubicin 68 haematologic malignancies 68 MDS MPD 68 Randomized Phase 68 REVLIMID R